M 10th Invitation to manufacturers of reproductive health products to submit an expression of interest (EOI) for product evaluation to the WHO Prequalification Team: medicines PDF
M 1st Invitation to manufacturers of medicinal products for treatment of Apnoea in Preterm infants to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Unit PDF
M 1st Invitation to Manufacturers of Biotherapeutic Products (BTPs) and Similar Biotherapeutic Products (SBPs)to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Team - Biotherapeutic Products (BTPs) PDF
M 1st Invitation to manufacturers of medicinal products for treatment of disorders caused by use of tobacco, to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Unit PDF
M 1st Invitation to manufacturers of medicinal products for treatment of infections in newborn and young infants and childhood pneumonia, to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Unit PDF
M 1st Invitation to manufacturers of medicinal products for treatment of multi-drug resistant bacterial infections, to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Unit PDF
M 1st Invitation to manufacturers of zinc products to submit an expression of interest (EOI) for product evaluation to the WHO Prequalification Team: medicines (10 November 2016) PDF
ID IVD IS M V VCP 2023 Joint UNICEF-UNFPA-WHO Meeting - Aligning WHO Normative and Prequalification Processes PDF
ID IVD IS M V VCP 2023 Joint UNICEF-UNFPA-WHO Meeting - Update and progress on the Coordinated Scientific Advice (CSA) PDF
M 22nd Invitation for Expression of Interest (EOI) for medicines against HIV infection and related diseases to submit an expression of interest (EOI) for product evaluation to the WHO Prequalification Unit PDF
M 22nd Invitation to manufacturers of antimalarial medicines to submit an expression of interest (EOI) for product evaluation to the WHO Prequalification Unit PDF
M 22nd Invitation to Manufacturers of Antituberculosis Medicines to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Unit PDF
M 2nd Invitation to Manufacturers of Human Insulin to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Team - Biotherapeutic Products (BTPs) PDF
M 2nd Invitation to Manufacturers of therapeutics against Ebola Virus Disease to submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit PDF
M 35th Invitation to manufacturers of active pharmaceutical ingredients (APIs) to submit an expression of interest (EOI) for API evaluation to the WHO Prequalification Unit PDF
M 3rd Biotherapeutic Product (BTP) and Similar Biotherapeutic Product (SBP) assessment training (Virtual) - 14 June 2024 - AGENDA PDF
M 3rd Biotherapeutic Product (BTP) and Similar Biotherapeutic Product (SBP) assessment training (Virtual) - 14 June 2024 - Agenda PDF
M 3rd Invitation to quality control laboratories (QCLs) to submit an expression of interest for prequalification to the WHO Prequalification Team: medicines (1 June 2011) PDF
M 4th Invitation to manufacturers of influenza-specific antiviral medicines to submit an expression of interest for product evaluation to the WHO Prequalification Team: medicines (August 2024) PDF
M 5th Invitation to manufacturers of medicinal products for treatment of hepatitis B and C to submit an expression of interest (EOI) for product evaluation to the WHO Prequalification Team: medicines PDF
M 8th Invitation to manufacturers of therapeutics against COVID-19 to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Unit PDF
M 9th Invitation to manufacturers of medicinal products for the treatment of neglected tropical diseases to submit an expression of interest (EOI) for product evaluation to the WHO Prequalification Unit PDF
M A quiet revolution in global public health: the World Health Organization's Prequalification of Medicines Programme
M Acceptance of non-plant-derived-artemisinin offers potential to increase access to malaria treatment (issued 8 May 2013)
M Additional Guidance for Submission of the Acceptability Study for Prequalification of Zinc Tablets and Oral Liquid (Solution) PDF
M Additional guidance on submission requirements for medroxyprogesterone acetate depot injection products using the Common Technical Document (CTD) format (1 August 2015) PDF
M Agenda - PQT Medicines 2nd Biotherapeutic Product (BTP) and Similar Biotherapeutic Product (SBP) Workshop for Manufacturers – 30 September 2022